The Alzheimer Europe Board held a meeting on 16 and 17 March 2026, at the Alzheimer Europe (AE) offices in Luxembourg. Jean Georges, Executive Director, Angela Bradshaw, Director for Research, Dianne Gove, Director for Public Involvement and Ethics, and Ana Diaz, Public Involvement Lead, were also in attendance.
On 16 March, the Board:
Approved the 2025 Annual Report, to be formally adopted by our Annual General Meeting (AGM) on 30 June
Selected the location for the 37th Alzheimer Europe Conference (37AEC) in 2027, which will be held in Belgrade (Serbia)
Adopted AE's position on blarcamesine (for more information, see: https://www.alzheimer-europe.org/news/alzheimer-europe-responds-european-medicines-agencys-assessment-blarcamesine).
The Board also discussed:
A position on the access to anti-amyloid treatments in Europe
The 2026 Anti-Stigma Award (to be launched on 15 April - watch this space!)
The survey for our 2026 Dementia in Europe Yearbook, focusing on National Dementia Strategies
The agenda for our AGM of 30 June
The call for nominations for the AE Board elections in June.
On 17 March, colleagues from the Research team and the Public Involvement team joined the Board meeting, sharing a number of updates on current EU-funded projects in which the organisation is involved.
The next Board meeting will take place on 4 May in Brussels (Belgium).
